Providing credible, evidence-based information about medical technologies, treatments, and models of care

Next Public Meeting of CTAF to Examine Newest Treatments for Hepatitis C

The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), will hold a public meeting on December 18, 2014 in Oakland, CA to assess the comparative effectiveness and value of multiple new, all-oral direct-acting antiviral agent (DAA) regimens for the treatment of hepatitis C. The review will cover treatments under review by the FDA, including those developed by Gilead Sciences, Inc. and AbbVie Inc., and possibly a third regimen developed by Bristol-Myers Squibb Co.

About CTAF

CTAF has long been recognized as one of the leading technology assessment programs in the country. In 2013, CTAF became a core program of the Institute for Clinical and Economic Review, and its approach has now been adapted to broaden stakeholder engagement and improve the application of CTAF products in practice and policy. Learn more »

 

Attend a Meeting

December 18, 2014
Oakland, CA

CTAF will assess the comparative effectiveness and value of multiple new, all-oral direct-acting antiviral agent (DAA) regimens for the treatment of hepatitis C. The review will cover treatments under review by the FDA, including those developed by Gilead Sciences, Inc.

Email Updates

Sign up to receive email notifications of upcoming CTAF meetings and new assessments. All fields required.